Integra LifeSciences (NSDQ:IART) and Dr. Reddy’s Laboratories (NYSE:RDY) inked an exclusive distribution agreement for the DuraGen Plus and suturable DuraGen Dural Regeneration Matrices in India. According to the deal, Dr. Reddy’s will market and distribute the medical devices throughout India. The DuraGen Plus Dural Regeneration Matrix is indicated as a dural susbtitute for the repair of […]
Organogenesis launches PuraPly antimicrobial clinical program
Organogenesis said today that it launched its PuraPly Antimicrobial clinical research program, which will evaluate patients treated with PuraPly AM for up to 12 weeks. The 1st studies have started enrolling patients, according to Organogenesis. The Canton, Mass.-based company’s PuraPly AM is a 510(k)-cleared device indicated for the management of acute and chronic wounds. The […]
The stem cell ‘skin gun’ that’s aiming to disrupt wound care
RenovaCare’s SkinGun uses a patient’s own stem cells to heal their wounds faster and more efficiently than a traditional skin graft. Pennsylvania state police officer Matthew Uram suffered severe second-degree burns to his face, right arm and leg after a friend’s bonfire got out of control. Uram was facing months of painful skin grafts, the […]
Origin treats first patients in study of nitric oxide for diabetic foot ulcers
Origin said today that it treated the 1st patients in its dose-ranging Genesis Phase IIb-equivalent trial. The study is evaluating therapeutic quantities of plasma-generated nitric oxide as a treatment for chronic diabetic foot ulcers. The 27-week trial is slated to enroll up to 100 patients. Patients will be randomized into 1 of 4 dosing regimens, […]
AcelRx touts Dsuvia data for burn victims
AcelRx Pharmaceuticals (NSDQ:ACRX) said today that it plans to present data from a study evaluating its Dsuvia pain reliever in patients with moderate-to-severe acute pain resulting from trauma or injury. The company’s Dsuvia candidate is composed of 30 sufentanil tablets delivered sublingually using a disposable, pre-filled single-dose applicator. Dsuvia is investigational and not approved in […]
Allergan closes $3B Acelity LifeCell buy
Acelity said today that it closed the sale of its regenerative medicine unit, LifeCell, to Allergan (NYSE:AGN) for $2.9 billion in cash. The deal brings LifeCell’s regenerative medicine and reconstructive portfolio to Allergan, joining a portfolio of medical aesthetics, breast implant and tissue expander product lines. Dublin-based Allergan said it expects to bring in $450 million in revenue this year, growing […]
MediWound touts Phase II study
MediWound (NSDQ:MDWD) touted data from a phase II trial of its EscharEx topical biological drug for debridement of chronic and other hard-to-heal wounds. The data includes a follow-up period of 6 months from the last treatment to 3 months from wound closure. The randomized phase II trial enrolled 73 patients with a variety of chronic and […]
Apligraf cell therapy changes genomic profile of chronic wound
Organogenesis Inc. said yesterday that its wound-healing cell therapy Apligraf is the 1st of its kind to significantly change the genomic profile of a treated chronic wound. The claim was supported by new research done at the University of Miami and published in the journal Science Translational Medicine. The team applied Apligraf to a chronic venous leg […]
InGeneron inks collaboration with German Accelerator Life Sciences
InGeneron said today that it landed a collaboration with the German Accelerator Life Sciences program, establishing an additional U.S. presence in Cambridge, Mass. The initiative is supported by the German Federal Ministry for Economic Affairs & Energy. The GALS program will provide InGeneron with a group of mentors to help leverage its network within the […]
Dipexium crashes after Locilex Phase III trials fail
Shares in Dipexium Pharmaceutical (NSDQ:DPRX) dived 84% today after it reported that its OneStep-1 and OneStep-2 Phase III clinical trials of Locilex in patients with mild infections of diabetic foot ulcers did not meet its primary or secondary clinical endpoints. Both trials failed to show any meaningful difference in wound closure rate between the Locilex arm and the […]
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn